MedPacto, Inc.
Financials
Valuation Metrics
MedPacto, Inc.'s Market Cap is ₩898B. At end of 2025 it was ₩2290B. Ranked #1306 of 2,436 in KR market (top 54%), #713 of 1,649 on KOSDAQ (top 43%), #143 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 89.80B KRW | KR#1,306/2,436 Sec#143/234 |
| Revenue | 4.79B KRW | KR#2,347/2,436 Sec#197/234 |
| Net Income | -13.21B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 45.36B KRW | KR#2,229/2,436 Sec#204/234 |
| Net Assets | 42.58B KRW | KR#1,980/2,436 Sec#172/234 |
| Employees | 57 | KR#1,967/2,436 Sec#173/234 |
| Value | ||
| P/B | 2.11x | KR#1,966/2,436 Sec#146/234 |
| P/S | 18.77x | KR#2,329/2,436 Sec#182/234 |
| FCF Yield | -15.01% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -31.03% | KR#2,173/2,436 Sec#174/234 |
| ROA | -29.13% | KR#2,293/2,436 Sec#196/234 |
| Op. Margin | -300.77% | KR#2,360/2,436 Sec#197/234 |
| Revenue Growth | 206.20% | KR#64/2,436 Sec#11/234 |
| Financial Health | ||
| Debt Ratio | 106.53% | KR#373/2,436 Sec#53/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -13.48B KRW | KR#1,801/2,436 Sec#162/234 |
| Cash | 8.82B KRW | KR#1,742/2,436 Sec#144/234 |
| Current Ratio | 26.54x | KR#19/2,436 Sec#7/234 |
| Performance | ||
| 1Y Return | -33.84% | KR#1,666/2,436 Sec#145/234 |
| 1M Return | -17.61% | KR#2,110/2,436 Sec#208/234 |
| From 52W High | -69.71% | KR#2,125/2,436 Sec#190/234 |
| 1Y MDD | -72.17% | KR#2,036/2,436 Sec#179/234 |
| Trading | ||
| Volume | 233,933 shares | KR#511/2,436 Sec#51/234 |
| Foreign Own. | 4.25% | KR#860/2,436 Sec#82/234 |
| Per Share | ||
| EPS | -385 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,242 KRW | KR#2,229/2,436 Sec#199/234 |
Company Info
The company, a bio company that spun off from Theragen Etex in 2013, was listed on the KOSDAQ market in 2019 as a technology growth company. It develops innovative new drugs for treating intractable cancer and chronic diseases, and discovers new drug candidate targets using advanced genome analysis technologies like next-generation sequencing and bioinformatics. Its flagship Baektoseoptip is under co-development for combination therapy with MSD and AstraZeneca. The company pursues precision medicine innovation with customized therapeutics and MA-B2 target antibody therapeutics. MedPacto, established in 2013, is headquartered in Seocho District, Seoul Metropolitan City.